Symbols / SEPN $25.14 +0.00%
SEPN Chart
About
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.13B |
| Enterprise Value | 761.48M | Income | -48.88M | Sales | 45.95M |
| Book/sh | 8.52 | Cash/sh | 8.71 | Dividend Yield | — |
| Payout | 0.00% | Employees | 130 | IPO | — |
| P/E | — | Forward P/E | -13.16 | PEG | — |
| P/S | 24.57 | P/B | 2.95 | P/C | — |
| EV/EBITDA | -9.62 | EV/Sales | 16.57 | Quick Ratio | 4.66 |
| Current Ratio | 4.73 | Debt/Eq | 6.19 | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | -1.91 | EPS Growth | — |
| Revenue Growth | 112.76% | Earnings | 2026-05-07 | ROA | -9.59% |
| ROE | -12.19% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -66.44% | Profit Margin | -106.37% | Shs Outstand | 44.91M |
| Shs Float | 22.90M | Short Float | 7.11% | Short Ratio | 5.75 |
| Short Interest | — | 52W High | 32.63 | 52W Low | 4.66 |
| Beta | — | Avg Volume | 304.60K | Volume | 333.75K |
| Target Price | $43.86 | Recom | Strong_buy | Prev Close | $25.14 |
| Price | $25.14 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$43.86
Mean price target
2. Current target
$25.14
Latest analyst target
3. DCF / Fair value
$7.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$25.14
Low
$34.00
High
$60.00
Mean
$43.86
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Truist Securities | Buy → Buy | $35 |
| 2026-03-03 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-12-23 | init | Jones Trading | — → Buy | $43 |
| 2025-12-19 | init | Raymond James | — → Strong Buy | $38 |
| 2025-12-15 | init | Truist Securities | — → Buy | $34 |
| 2025-11-14 | up | Wells Fargo | Equal-Weight → Overweight | $28 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-09-05 | reit | Cantor Fitzgerald | Overweight → Overweight | $25 |
| 2025-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-06-23 | init | HC Wainwright & Co. | — → Buy | $26 |
| 2025-05-16 | main | Cantor Fitzgerald | Overweight → Overweight | $25 |
| 2025-05-16 | main | Wells Fargo | Equal-Weight → Equal-Weight | $18 |
| 2025-03-28 | main | Wells Fargo | Equal-Weight → Equal-Weight | $11 |
| 2025-02-18 | down | Wells Fargo | Overweight → Equal-Weight | $14 |
| 2025-02-11 | reit | Cantor Fitzgerald | Overweight → Overweight | $50 |
| 2024-11-19 | init | Cantor Fitzgerald | — → Overweight | $50 |
| 2024-11-19 | init | Wells Fargo | — → Overweight | $43 |
| 2024-11-19 | init | JP Morgan | — → Overweight | $38 |
- Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st Mon, 16 Mar 2026 13
- Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat Sun, 15 Mar 2026 10
- Avoiding Lag: Real-Time Signals in (SEPN) Movement - Stock Traders Daily Sun, 15 Mar 2026 19
- Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance Mon, 09 Mar 2026 21
- Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail hu, 12 Mar 2026 10
- Septerna (SEPN) CPO exercises options, then sells 70,453 shares - Stock Titan hu, 05 Mar 2026 00
- $SEPN stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 08
- Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat Sat, 14 Mar 2026 07
- How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - Sahm Sun, 08 Mar 2026 08
- SEPN - Septerna, Inc. Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 17
- Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance hu, 09 Oct 2025 07
- Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat Wed, 11 Mar 2026 14
- Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)? - Yahoo Finance ue, 03 Mar 2026 14
- Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan Sun, 01 Mar 2026 08
- Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat Sat, 14 Mar 2026 05
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 70453 | 129456.0 | — | Conversion of Exercise of derivative security at price 1.55 - 2.76 per share. | SHAIKHLY SAMIRA | Officer | — | 2026-03-02 00:00:00 | D |
| 1 | 70453 | 1979838.0 | — | Sale at price 27.51 - 28.14 per share. | SHAIKHLY SAMIRA | Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 4000 | 27240.0 | — | Conversion of Exercise of derivative security at price 6.81 per share. | BHATT ELIZABETH | President | — | 2026-02-18 00:00:00 | D |
| 3 | 4000 | 115860.0 | — | Sale at price 28.46 - 29.58 per share. | BHATT ELIZABETH | President | — | 2026-02-18 00:00:00 | D |
| 4 | 3501 | 63223.0 | — | Sale at price 18.06 per share. | LONG DANIEL D | Officer | — | 2025-11-10 00:00:00 | D |
| 5 | 23008 | 94367.0 | — | Conversion of Exercise of derivative security at price 2.76 - 6.81 per share. | KLEIN UWE | Officer | — | 2025-08-18 00:00:00 | D |
| 6 | 55000 | 151800.0 | — | Conversion of Exercise of derivative security at price 2.76 per share. | FINER JEFFREY | Chief Executive Officer | — | 2025-04-03 00:00:00 | D |
| 7 | 13319 | 92270.0 | — | Purchase at price 6.93 per share. | EZEKOWITZ ALAN | Director | — | 2025-03-07 00:00:00 | D |
| 8 | 86681 | 515934.0 | — | Purchase at price 5.82 - 6.35 per share. | EZEKOWITZ ALAN | Director | — | 2025-03-06 00:00:00 | D |
| 9 | 10000 | 56867.0 | — | Purchase at price 5.59 - 5.85 per share. | LABRUCHERIE GILBERT M JR | Chief Financial Officer | — | 2025-02-27 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 6.76M | 0.00 |
| TaxRateForCalcs | 0.01 | 0.14 | 0.00 |
| NormalizedEBITDA | -79.42M | -92.33M | -27.39M |
| TotalUnusualItems | 0.00 | 47.62M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 47.62M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -71.80M | 4.18M | -27.68M |
| ReconciledDepreciation | 1.40M | 848.00K | 577.00K |
| EBITDA | -79.42M | -44.70M | -27.39M |
| EBIT | -80.82M | -45.55M | -27.97M |
| NetInterestIncome | 8.62M | 2.79M | 291.00K |
| InterestIncome | 8.62M | 2.79M | 291.00K |
| NormalizedIncome | -71.80M | -36.68M | -27.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -71.80M | 4.18M | -27.68M |
| TotalExpenses | 81.90M | 45.70M | 27.97M |
| TotalOperatingIncomeAsReported | -80.82M | 2.08M | -27.97M |
| DilutedAverageShares | 9.89M | 19.50M | 19.50M |
| BasicAverageShares | 9.89M | 19.50M | 19.50M |
| DilutedEPS | -7.26 | 0.03 | -1.42 |
| BasicEPS | -7.26 | 0.03 | -1.42 |
| DilutedNIAvailtoComStockholders | -71.80M | 629.00K | -27.68M |
| AverageDilutionEarnings | 62.00K | ||
| NetIncomeCommonStockholders | -71.80M | 567.00K | -27.68M |
| OtherunderPreferredStockDividend | 0.00 | 3.61M | 0.00 |
| NetIncome | -71.80M | 4.18M | -27.68M |
| NetIncomeIncludingNoncontrollingInterests | -71.80M | 4.18M | -27.68M |
| NetIncomeContinuousOperations | -71.80M | 4.18M | -27.68M |
| TaxProvision | -498.00K | 691.00K | 0.00 |
| PretaxIncome | -72.30M | 4.87M | -27.68M |
| OtherIncomeExpense | -90.00K | 47.63M | |
| OtherNonOperatingIncomeExpenses | -90.00K | 10.00K | |
| SpecialIncomeCharges | 0.00 | 47.62M | 0.00 |
| GainOnSaleOfPPE | 0.00 | 47.62M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 8.62M | 2.79M | 291.00K |
| InterestIncomeNonOperating | 8.62M | 2.79M | 291.00K |
| OperatingIncome | -80.82M | -45.55M | -27.97M |
| OperatingExpense | 81.90M | 45.70M | 27.97M |
| ResearchAndDevelopment | 65.34M | 35.98M | 22.04M |
| SellingGeneralAndAdministration | 16.56M | 9.72M | 5.92M |
| GeneralAndAdministrativeExpense | 16.56M | 9.72M | 5.92M |
| OtherGandA | 16.56M | 9.72M | 5.92M |
| TotalRevenue | 1.07M | 151.00K | 0.00 |
| OperatingRevenue | 1.07M | 151.00K | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 44.42M | 42.00M | 42.00M |
| ShareIssued | 44.42M | 42.00M | 42.00M |
| TotalDebt | 25.48M | 12.57M | 710.00K |
| TangibleBookValue | 420.05M | -38.37M | -44.20M |
| InvestedCapital | 420.05M | -38.37M | -44.20M |
| WorkingCapital | 343.98M | 105.76M | 26.35M |
| NetTangibleAssets | 420.05M | -38.37M | -44.20M |
| CapitalLeaseObligations | 25.48M | 12.57M | 710.00K |
| CommonStockEquity | 420.05M | -38.37M | -44.20M |
| TotalCapitalization | 420.05M | -38.37M | -44.20M |
| TotalEquityGrossMinorityInterest | 420.05M | -38.37M | -44.20M |
| StockholdersEquity | 420.05M | -38.37M | -44.20M |
| GainsLossesNotAffectingRetainedEarnings | 56.00K | 0.00 | |
| OtherEquityAdjustments | 56.00K | ||
| RetainedEarnings | -118.37M | -46.58M | -50.76M |
| AdditionalPaidInCapital | 538.32M | 8.20M | 6.55M |
| CapitalStock | 44.00K | 3.00K | 3.00K |
| CommonStock | 44.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 36.51M | 169.24M | 80.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 23.66M | 162.33M | 74.78M |
| OtherNonCurrentLiabilities | 33.00K | 546.00K | 83.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 149.22M | 74.69M |
| LongTermDebtAndCapitalLeaseObligation | 23.62M | 12.57M | 0.00 |
| LongTermCapitalLeaseObligation | 23.62M | 12.57M | 0.00 |
| CurrentLiabilities | 12.85M | 6.91M | 5.54M |
| OtherCurrentLiabilities | 78.00K | 85.00K | 50.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.85M | 710.00K | |
| CurrentCapitalLeaseObligation | 1.85M | 0.00 | 710.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.13M | 2.95M | 1.71M |
| PayablesAndAccruedExpenses | 6.79M | 3.88M | 3.08M |
| CurrentAccruedExpenses | 3.59M | 1.04M | 6.00K |
| Payables | 3.20M | 2.84M | 3.07M |
| TotalTaxPayable | 0.00 | 200.00K | 0.00 |
| IncomeTaxPayable | 0.00 | 200.00K | 0.00 |
| AccountsPayable | 3.20M | 2.64M | 3.07M |
| TotalAssets | 456.55M | 130.87M | 36.12M |
| TotalNonCurrentAssets | 99.73M | 18.19M | 4.23M |
| OtherNonCurrentAssets | 1.17M | 1.00M | 1.12M |
| InvestmentsAndAdvances | 69.87M | 0.00 | |
| InvestmentinFinancialAssets | 69.87M | 0.00 | |
| AvailableForSaleSecurities | 69.87M | ||
| NetPPE | 28.69M | 17.19M | 3.10M |
| AccumulatedDepreciation | -2.93M | -1.62M | -798.00K |
| GrossPPE | 31.62M | 18.81M | 3.90M |
| Leases | 717.00K | 389.00K | 0.00 |
| OtherProperties | 29.28M | 17.49M | 3.67M |
| MachineryFurnitureEquipment | 1.62M | 931.00K | 231.00K |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 356.82M | 112.68M | 31.89M |
| OtherCurrentAssets | 200.00K | 92.00K | 204.00K |
| PrepaidAssets | 4.58M | 1.33M | 1.08M |
| Receivables | 1.12M | 22.78M | 0.00 |
| OtherReceivables | 22.62M | ||
| AccruedInterestReceivable | 953.00K | ||
| AccountsReceivable | 171.00K | 151.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 350.92M | 88.48M | 30.61M |
| OtherShortTermInvestments | 112.73M | 0.00 | |
| CashAndCashEquivalents | 238.20M | 88.48M | 30.61M |
| CashEquivalents | 86.57M | 29.61M | |
| CashFinancial | 1.91M | 1.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -69.57M | -41.60M | -24.59M |
| RepurchaseOfCapitalStock | -1.00K | -1.00K | |
| IssuanceOfCapitalStock | 377.73M | 74.52M | 29.97M |
| CapitalExpenditure | -2.10M | -2.88M | -1.29M |
| IncomeTaxPaidSupplementalData | 232.00K | 75.00K | 0.00 |
| EndCashPosition | 239.10M | 89.39M | 31.47M |
| BeginningCashPosition | 89.39M | 31.47M | 26.01M |
| ChangesInCash | 149.71M | 57.92M | 5.46M |
| FinancingCashFlow | 377.78M | 74.52M | 30.05M |
| CashFlowFromContinuingFinancingActivities | 377.78M | 74.52M | 30.05M |
| ProceedsFromStockOptionExercised | 52.00K | 0.00 | 82.00K |
| NetPreferredStockIssuance | 74.94M | 74.52M | 29.97M |
| PreferredStockIssuance | 74.94M | 74.52M | 29.97M |
| NetCommonStockIssuance | 302.79M | -1.00K | |
| CommonStockPayments | -1.00K | -1.00K | |
| CommonStockIssuance | 302.79M | 0.00 | |
| InvestingCashFlow | -160.60M | 22.12M | -1.29M |
| CashFlowFromContinuingInvestingActivities | -160.60M | 22.12M | -1.29M |
| NetOtherInvestingChanges | 22.62M | 25.00M | |
| NetInvestmentPurchaseAndSale | -181.12M | 0.00 | |
| SaleOfInvestment | 32.27M | 0.00 | |
| PurchaseOfInvestment | -213.39M | 0.00 | |
| NetPPEPurchaseAndSale | -2.10M | -2.88M | -1.29M |
| PurchaseOfPPE | -2.10M | -2.88M | -1.29M |
| OperatingCashFlow | -67.47M | -38.72M | -23.30M |
| CashFlowFromContinuingOperatingActivities | -67.47M | -38.72M | -23.30M |
| ChangeInWorkingCapital | 248.00K | 926.00K | 1.75M |
| ChangeInOtherWorkingCapital | 448.00K | -770.00K | -573.00K |
| ChangeInOtherCurrentAssets | -170.00K | 165.00K | 244.00K |
| ChangeInPayablesAndAccruedExpense | 4.29M | 1.82M | 3.10M |
| ChangeInAccruedExpense | 3.56M | 2.47M | 1.37M |
| ChangeInPayable | 723.00K | -653.00K | 1.73M |
| ChangeInAccountPayable | 723.00K | -653.00K | 1.73M |
| ChangeInPrepaidAssets | -4.30M | -136.00K | -1.02M |
| ChangeInReceivables | -20.00K | -151.00K | 0.00 |
| ChangesInAccountReceivables | -20.00K | -151.00K | 0.00 |
| OtherNonCashItems | 1.43M | 837.00K | 530.00K |
| StockBasedCompensation | 3.15M | 1.62M | 1.52M |
| AmortizationOfSecurities | -1.41M | 0.00 | |
| DeferredTax | -491.00K | 491.00K | 0.00 |
| DeferredIncomeTax | -491.00K | 491.00K | 0.00 |
| DepreciationAmortizationDepletion | 1.40M | 848.00K | 577.00K |
| DepreciationAndAmortization | 1.40M | 848.00K | 577.00K |
| OperatingGainsLosses | -47.62M | ||
| GainLossOnSaleOfPPE | 30.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -71.80M | 4.18M | -27.68M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SEPN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|